The global preclinical imaging market was valued at USD 1.0 billion in 2025 and is projected to grow from USD 1.1 billion in 2026 to USD 1.6 billion by 2033, registering a CAGR of 5.6% from 2026 to 2033. North America dominated the market in 2025, accounting for 46.4% of global revenue.

Market growth is being driven by increasing investments in drug discovery and development, the rising prevalence of chronic diseases, growing adoption of non-invasive imaging technologies, and the expanding use of advanced imaging platforms in preclinical research.

According to Grand View Research estimates, the global preclinical imaging market is expected to increase from approximately USD 1.05 billion in 2025 to USD 1.11 billion in 2026 and USD 1.63 billion by 2033, representing a CAGR of 5.6% during the forecast period.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

Preclinical Imaging Market: Key Market Statistics

What Is Driving the Preclinical Imaging Market?

The expansion of the preclinical imaging market is primarily supported by the growing need for accurate, non-invasive techniques to evaluate disease progression, therapeutic response, and biological mechanisms before potential treatments enter human clinical trials.

Key market growth drivers include:

• Increasing investment in pharmaceutical and biotechnology research and development
• Rising prevalence of chronic diseases and cancer
• Growing demand for non-invasive and longitudinal imaging techniques
• Increasing adoption of advanced preclinical imaging modalities
• Expansion of translational research programs
• Greater use of animal models in drug discovery and development
• Government grants and funding for preclinical research
• Growing demand for real-time visualization of cellular and molecular processes

Go Deeper! Ask Prism AI

about the Global preclinical imaging market. Get instant answers to questions related to market sizing, growth drivers & their impact, and more.

Preclinical Imaging Modalities

Preclinical imaging encompasses a range of technologies used to visualize anatomical structures, physiological functions, disease mechanisms, and molecular processes in animal models.

Major preclinical imaging modalities include:

• Magnetic resonance imaging (MRI)
• Computed tomography (CT)
• Positron emission tomography (PET)
• Single-photon emission computed tomography (SPECT)
• Ultrasound
• Optical imaging

These technologies enable researchers to monitor biological processes non-invasively and generate quantitative information at different stages of drug discovery and disease research.

Growing Use of PET Imaging in Preclinical Research

The expanding use of PET imaging demonstrates the growing importance of molecular imaging in translational research. A 2025 Nature Communications study investigating type I conventional dendritic cell (cDC1) immunotherapy used PET imaging to non-invasively monitor immune responses and tumor dynamics in preclinical cancer models.

Researchers used PET scans to evaluate enhanced infiltration and activation of tissue-resident memory T cells following cDC1 vaccination. Imaging results were correlated with tumor control and prevention of disease relapse.

This type of imaging provides researchers with spatial and temporal information about biological responses within tumors. Such capabilities can help researchers evaluate therapeutic mechanisms, assess treatment effectiveness, monitor disease progression, and optimize treatment strategies before advancing candidates into human clinical trials.

Download a free sample report or claim your copy of this full market intelligence report

Role of Chronic Disease Research in Market Growth

The increasing prevalence of chronic diseases, particularly cancer and other complex conditions, is creating greater demand for sophisticated preclinical research models and imaging technologies.

Developed countries with established biomedical research infrastructure and substantial R&D investment are major contributors to this demand. Pharmaceutical companies, biotechnology companies, academic institutions, and research organizations increasingly use preclinical imaging to evaluate potential treatments and understand disease mechanisms.

The use of disease-specific animal models is also expanding. Genetically engineered mice and other specialized models are increasingly combined with advanced imaging systems to enable dynamic monitoring of disease development and therapeutic response.

As a result, demand is increasing for imaging platforms capable of supporting repeated and longitudinal imaging protocols while providing quantitative information throughout the research process.

Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs.

North America Preclinical Imaging Market

North America was the largest regional market in 2025, accounting for 46.4% of global revenue. The region benefits from well-established biomedical research infrastructure, significant pharmaceutical and biotechnology R&D expenditure, advanced healthcare systems, and strong adoption of innovative imaging technologies.

The U.S. preclinical imaging market accounted for the largest revenue share within the region in 2025. The country's extensive pharmaceutical research ecosystem, academic research institutions, government funding programs, and established preclinical research capabilities continue to support demand for advanced imaging systems.

Preclinical Imaging Market Size and Forecast, 2025–2033

The global preclinical imaging market is expected to maintain steady growth throughout the forecast period.

• 2025: USD 1.0 billion
• 2026: USD 1.1 billion
• 2033: USD 1.6 billion
• CAGR, 2026–2033: 5.6%
• North America share, 2025: 46.4%
• Modality segment share, 2025: 63.92%

The market outlook is supported by continued investment in drug discovery, increasing use of animal disease models, technological advancements in imaging modalities, and growing demand for non-invasive approaches to preclinical research.

Explore the full list of profiled companies operating in this market with recent strategic initiatives

Preclinical Imaging Market: Competitive Landscape

The preclinical imaging market includes established imaging technology providers and specialized companies serving pharmaceutical, biotechnology, academic, and research institutions.

Key companies operating in the preclinical imaging market include:

• Cubresa Inc.
• Bruker Corporation
• Revvity, Inc.
• FUJIFILM VisualSonics
• Mediso Ltd.
• Rigaku (MILabs B.V.)
• MR Solutions
• Aspect Imaging

Explore our dedicated business services:

U.S. Healthcare Facility Mapping & Intelligence Platform: Get facility-level intelligence to guide smarter decisions. Sign up Today